[Genetic diagnosis of leukemia: diagnosis of relapse and complete remission, and prediction of leukemia onset]
- PMID: 10804819
[Genetic diagnosis of leukemia: diagnosis of relapse and complete remission, and prediction of leukemia onset]
Abstract
Wilms' tumor gene WT1 mRNA is a new marker of leukemic blast cells for AML, ALL, and CML. Minimal residual disease(MRD) of leukemia can be detected at frequencies as low as 1 in 10(3) to 10(4) normal bone marrow cells and 1 in 10(5) normal peripheral blood mononuclear cells by means of the quantitation of WT1 mRNA(WT1 assay) using reverse transcriptase-polymerase chain reaction. Thus, the WT1 assay makes it possible to rapidly assess the effectiveness of treatment and to evaluate the degree of eradication of leukemic cell in individual leukemia patients. Furthermore, WT1 assay can continuously assess the disease progression of myelodysplastic syndromes(MDS) and predict the evolution of MDS to overt AML within 6 months.
Similar articles
-
[Development of a new inspection diagnostic method: genetic screening of cancer].Rinsho Byori. 2004 May;52(5):426-9. Rinsho Byori. 2004. PMID: 15206129 Japanese.
-
Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias.Leukemia. 1995 Jun;9(6):1060-7. Leukemia. 1995. PMID: 7596170
-
[Expression of Wilms' tumor gene (WT1) in leukemias and its clinical implication].Zhonghua Xue Ye Xue Za Zhi. 1998 Jan;19(1):16-9. Zhonghua Xue Ye Xue Za Zhi. 1998. PMID: 10921096 Chinese.
-
Wilms tumor gene (WT1) as a new marker for the detection of minimal residual disease in leukemia.Leuk Lymphoma. 1998 Jun;30(1-2):55-61. doi: 10.3109/10428199809050929. Leuk Lymphoma. 1998. PMID: 9669676 Review.
-
The role of Wilms' tumor genes.J Med Invest. 1999 Aug;46(3-4):130-40. J Med Invest. 1999. PMID: 10687307 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous